Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 118104
1. Kuusk T, Pulliainen K, Vaarala MH: External beam radiation for the treatment of castration-resistant prostate cancer following primary hormonal therapy with androgen ablation: Analysis and outcome of 21 patients. Mol Clin Oncol; 2017 Mar;6(3):428-432
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] External beam radiation for the treatment of castration-resistant prostate cancer following primary hormonal therapy with androgen ablation: Analysis and outcome of 21 patients.
  • Patients who undergo early androgen-deprivation therapy for prostate cancer may eventually develop castration-resistant prostate cancer.
  • However, no optimal treatment for non-metastasized castration-resistant prostate cancer has yet been established.
  • In the present retrospective, single-institutional study, the radiotherapy (RT) outcomes were evaluated in patients who underwent androgen-deprivation therapy for non-metastatic prostate cancer and subsequently developed castration-resistant disease.
  • Following a thorough chart review, the data of 21 patients with castration-resistant prostate cancer who were treated between 2000 and 2010 with external beam radiation therapy (EBRT) at a prostate radiation dose of >45 Gy were evaluated.
  • A total of 18 patients succumbed to the disease during follow-up, with a mean survival of 3 years after RT.
  • Prostate-specific survival time was negatively associated with the Gleason score at diagnosis.
  • The prostate-specific antigen (PSA) concentration prior to RT was a prognostic factor for biochemical recurrence of prostate cancer after RT, as well as for prostate cancer-specific survival.
  • Finally, the multivariate analysis revealed that age, PSA concentration prior to RT and a high Gleason score were independent prognostic factors for prostate cancer-specific survival.
  • Overall, our study findings demonstrated that disease progression was common after EBRT for castration-resistant prostate cancer and that survival was limited.
  • However, young patients and those with low-risk disease at the time of diagnosis may benefit from RT.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2015 Sep;68(3):386-96 [25484142.001]
  • [Cites] J Cancer Res Clin Oncol. 2013 Nov;139(11):1955-60 [24057645.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5B):3141-5 [15510602.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):e205-11 [22342096.001]
  • [Cites] J Urol. 2007 Jun;177(6):2106-31 [17509297.001]
  • [Cites] Int J Urol. 1999 Apr;6(4):187-91 [10226836.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23 (9):1962-8 [15774789.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):759-65 [19327908.001]
  • [Cites] BJU Int. 2009 Nov;104(10):1462-6 [19522869.001]
  • [Cites] Ann Intern Med. 2008 Mar 18;148(6):435-48 [18252677.001]
  • [Cites] Am J Clin Oncol. 2004 Jun;27(3):264-8 [15170145.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1708-14 [16544313.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Nov 1;33(4):907-12 [7591901.001]
  • [Cites] Eur Urol. 2014 Feb;65(2):467-79 [24321502.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2015 Jan;27(1):16-21 [25445554.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):372-9 [15145150.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95 [15663992.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):2918-25 [15860850.001]
  • (PMID = 28451427.001).
  • [ISSN] 2049-9450
  • [Journal-full-title] Molecular and clinical oncology
  • [ISO-abbreviation] Mol Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; prostate cancer / radiation / retrospective chart review
  •  go-up   go-down


2. Bell LJ, Eade T, Kneebone A, Hruby G, Alfieri F, Bromley R, Grimberg K, Barnes M, Booth JT: Initial experience with intra-fraction motion monitoring using Calypso guided volumetric modulated arc therapy for definitive prostate cancer treatment. J Med Radiat Sci; 2017 Mar;64(1):25-34
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial experience with intra-fraction motion monitoring using Calypso guided volumetric modulated arc therapy for definitive prostate cancer treatment.
  • INTRODUCTION: Accurate delivery of radiation while reducing dose to organs at risk is essential in prostate treatment.
  • Three patients had Calypso beacons inserted into their prostate.
  • Prostate rotation was largest in the pitch direction and 28 fractions exceeded the 10° tolerance.
  • [MeSH-major] Dose Fractionation. Movement. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 The Authors. Journal of Medical Radiation Sciences published by Wiley Publishing Asia Pty Ltd on behalf of Australian Society of Medical Imaging and Radiation Therapy and New Zealand Institute of Medical Radiation Technology.
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1579-85 [20472357.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1099-105 [17336216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1088-98 [17187940.001]
  • [Cites] Med Phys. 2014 Feb;41(2):020702 [24506591.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):1017-25 [25832692.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):477-83 [23523325.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105 [12128107.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):51-63 [12504036.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):528-34 [16690435.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):682-9 [17398026.001]
  • (PMID = 28263041.001).
  • [ISSN] 2051-3909
  • [Journal-full-title] Journal of medical radiation sciences
  • [ISO-abbreviation] J Med Radiat Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; calypso / implementation / intra-fraction motion / prostate / radiation treatment
  •  go-up   go-down


3. Javanmard B, Hassanzadeh Haddad A, Yaghoobi M, Lotfi B: Diode laser ablation of prostate and channel transurethral resection of prostate in patients with prostate cancer and bladder outlet obstruction symptoms. Urol J; 2014 Jul-Aug;11(4):1788-92
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diode laser ablation of prostate and channel transurethral resection of prostate in patients with prostate cancer and bladder outlet obstruction symptoms.
  • PURPOSE: To evaluate the efficacy of diode laser ablation of prostate for treating lower urinary tract symptoms (LUTS) in patients with locally advanced prostate cancer and comparing results with palli­ative transurethral resection of prostate (pTURP).
  • MATERIALS AND METHODS: Thirty-six known cases of locally advanced prostate cancer with a maximum urinary flow rate (Qmax) of 12 mL per second or less and an International Prostate Symptom Score (IPSS) of 20 or more were included in this study.
  • The first group underwent pTURP and for the second group diode laser ablation of prostate was done.
  • CONCLUSION: Diode laser ablation of prostate and pTURP, both improved significantly IPSS, PVR and Qmax.
  • [MeSH-major] Ablation Techniques / instrumentation. Carcinoma / surgery. Lasers, Semiconductor / therapeutic use. Palliative Care. Prostatic Neoplasms / surgery. Prostatism / surgery. Urinary Bladder Neck Obstruction / surgery
  • [MeSH-minor] Aged. Humans. Length of Stay. Male. Middle Aged. Operative Time. Time Factors. Transurethral Resection of Prostate. Urinary Catheterization. Urodynamics

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25194077.001).
  • [ISSN] 1735-546X
  • [Journal-full-title] Urology journal
  • [ISO-abbreviation] Urol J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Iran
  •  go-up   go-down


Advertisement
4. Hosni A, Rosewall T, Craig T, Kong V, Bayley A, Berlin A, Bristow R, Catton C, Warde P, Chung P: The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer. Radiat Oncol; 2017 Mar 09;12(1):50
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer.
  • BACKGROUND: This study aimed to investigate the tolerability and impact of milk of magnesia (MoM) on interfraction rectal filling during prostate cancer radiotherapy.
  • METHODS: Two groups were retrospectively identified, each consisting of 40 patients with prostate cancer treated with radiotherapy to prostate+/-seminal vesicles, with daily image-guidance in 78Gy/39fractions/8 weeks.
  • [MeSH-major] Artifacts. Intestine, Small / physiology. Prostatic Neoplasms / radiotherapy. Radiotherapy, Image-Guided / methods

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1611-21 [15590193.001]
  • [Cites] Eur Urol. 2011 Dec;60(6):1133-9 [21889832.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):125-9 [22330997.001]
  • [Cites] Radiother Oncol. 2010 Jun;95(3):277-82 [20451274.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72 (2):456-66 [18374517.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1072-8 [19783378.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):548-53 [16545919.001]
  • [Cites] Strahlenther Onkol. 2014 Aug;190(8):758-61 [24760248.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):525-33 [10348281.001]
  • [Cites] Radiother Oncol. 2011 Dec;101(3):471-8 [21903283.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):646-50 [24054874.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1418-24 [17241751.001]
  • [Cites] Radiother Oncol. 1999 Feb;50(2):225-34 [10368047.001]
  • [Cites] Jpn J Radiol. 2009 Jun;27(5):205-12 [19554413.001]
  • [Cites] JAMA. 1997 May 14;277(18):1445-51 [9145716.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1279-86 [18572088.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):965-73 [15989996.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1405-18 [19616743.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):653-60 [22099039.001]
  • [Cites] Acta Oncol. 2014 Apr;53(4):569-71 [24237391.001]
  • (PMID = 28279179.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Laxatives
  • [Keywords] NOTNLM ; Bowel preparation / Laxative / Prostate cancer / Radiotherapy / Rectum
  •  go-up   go-down


5. Williams F, Imm KR, Colditz GA, Housten AJ, Yang L, Gilbert KL, Drake BF: Physician role in physical activity for African-American males undergoing radical prostatectomy for prostate cancer. Support Care Cancer; 2017 Apr;25(4):1151-1158

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physician role in physical activity for African-American males undergoing radical prostatectomy for prostate cancer.
  • PURPOSE: Physical activity is recognized as a complementary therapy to improve physical and physiological functions among prostate cancer survivors.
  • Little is known about communication between health providers and African-American prostate cancer patients, a high risk population, regarding the health benefits of regular physical activity on their prognosis and recovery.
  • This study explores African-American prostate cancer survivors' experiences with physical activity prescription from their physicians.
  • METHODS: Three focus group interviews were conducted with 12 African-American prostate cancer survivors in May 2014 in St. Louis, MO.
  • These findings highlight the importance of physical activity communication and prescription for prostate cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27999951.001).
  • [ISSN] 1433-7339
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; African-American / Physical activity / Physician / Prescription/communication / Prostate cancer / Survivor
  •  go-up   go-down


6. Shahriari M, Dehghan M, Pahlavanzadeh S, Hazini A: Effects of progressive muscle relaxation, guided imagery and deep diaphragmatic breathing on quality of life in elderly with breast or prostate cancer. J Educ Health Promot; 2017;6:1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of progressive muscle relaxation, guided imagery and deep diaphragmatic breathing on quality of life in elderly with breast or prostate cancer.
  • BACKGROUND AND OBJECTIVES: Due to the increasing number of elderly and an increase in the number of cases of cancer by age, cancer is a common problem in the elderly.
  • For elderly patients with cancer, the disease and its treatment can have long-term negative effects on their quality of life (QoL).
  • The purpose of this study was to evaluate the effect of progressive muscle relaxation, body image and deep diaphragmatic breathing on the QoL in the elderly with cancer.
  • MATERIALS AND METHODS: This study was a randomized controlled trial in which 50 elderly patients with breast or prostate cancer were randomized into study and control groups.
  • European Organization for Research and Treatment of Cancer and QoL Questionnaire-Core questionnaires was completed before, after and 6 weeks after the intervention for the patients in both groups simultaneously.
  • CONCLUSIONS: The findings indicated that concurrent application of progressive muscle relaxation, guided imagery, and deep diaphragmatic breathing would improve QoL in the elderly with breast or prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nurs Forum. 2006 Apr-Jun;41(2):60-77 [16669984.001]
  • [Cites] Indian J Med Res. 2009 May;129(5):603-8 [19675392.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1944-51 [12743147.001]
  • [Cites] Psychooncology. 2007 Nov;16(11):971-9 [17311247.001]
  • [Cites] Complement Ther Clin Pract. 2008 Aug;14(3):185-94 [18640630.001]
  • [Cites] J Child Psychol Psychiatry. 2004 Oct;45(7):1199-208 [15335340.001]
  • [Cites] CA Cancer J Clin. 2013 Jan;63(1):11-30 [23335087.001]
  • [Cites] Support Care Cancer. 2005 Oct;13(10):826-33 [15856335.001]
  • [Cites] Psychooncology. 2003 Apr-May;12(3):254-66 [12673809.001]
  • [Cites] Cancer Nurs. 2002 Dec;25(6):432-5 [12464834.001]
  • [Cites] J Pain Symptom Manage. 2010 Jan;39(1):126-38 [19900778.001]
  • [Cites] Ann Oncol. 2010 May;21 Suppl 3:iii83-89 [20427365.001]
  • [Cites] Support Care Cancer. 2002 Apr;10(3):237-46 [11904789.001]
  • [Cites] Cancer. 2009 Sep 15;115(18 Suppl):4283-97 [19731348.001]
  • [Cites] Support Cancer Ther. 2007 Sep 1;4(4):247-50 [18632524.001]
  • (PMID = 28546966.001).
  • [ISSN] 2277-9531
  • [Journal-full-title] Journal of education and health promotion
  • [ISO-abbreviation] J Educ Health Promot
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Keywords] NOTNLM ; Cancer / diaphragmatic breathing / elderly / guided imagery / progressive muscle relaxation / quality of life
  •  go-up   go-down


7. Jeong HJ, Kwon DD: Continence rate and oncological feasibility after total transurethral resection of the prostate as an alternative therapy for the treatment of prostate cancer: a pilot study. Int Neurourol J; 2011 Dec;15(4):222-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continence rate and oncological feasibility after total transurethral resection of the prostate as an alternative therapy for the treatment of prostate cancer: a pilot study.
  • PURPOSE: The value of total transurethral resection of prostate cancer (TURPC) as an alternative therapy was first recognized by Hans J. Reuter.
  • Thus, we conducted the study of prospectively collected data to verify total TURPC as an alternative therapy forlocalized prostate cancer.
  • METHODS: From January 2008 to July 2011, 14 patients with a mean age of 76.1 years (range, 66 to 89 years) with clinically localized prostate cancer were treated by prostatic resection by the corresponding author with curative intention.
  • RESULTS: The mean duration of TURPC was 51.7 minutes (range, 30 to 120 minutes) and the mean amount of prostatic tissue resected was 21.2 g (range, 5 to 66 g).
  • Three patients in the high-risk group did not achieve a prostate specific antigen (PSA) nadir of ≤0.2 ng/mL.
  • CONCLUSIONS: According to our results, transurethral resection for prostate cancer can be performed with reasonable oncological results.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22259737.001).
  • [ISSN] 2093-6931
  • [Journal-full-title] International neurourology journal
  • [ISO-abbreviation] Int Neurourol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3256308
  • [Keywords] NOTNLM ; Prostate-specific antigen / Prostatic neoplasms / Transurethral resection of prostate / Urinary incontinence
  •  go-up   go-down


8. Paoluzzi M, Losa A, Cerboneschi V, Colosimo C, Fontana N, Mangili P, Mignogna M, Nava L, Ravaglia V: Prostate-specific antigen percentage: An early predictive tool after iodine-125 interstitial brachytherapy for prostate cancer. Brachytherapy; 2017 Jun 19;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate-specific antigen percentage: An early predictive tool after iodine-125 interstitial brachytherapy for prostate cancer.
  • BACKGROUND: After interstitial prostate iodine-125 brachytherapy (BT), prostate-specific antigen (PSA) evolution in time could predict overall biochemical relapse, but, considering the single patient, it is influenced by the presentation PSA amount and by the prostatic volume.
  • PURPOSE: To determine the usefulness of PSA percentage (PP) defined as the rate between PSA presented by a patient at time "t" and the PSA that the same patient had presented at the time of diagnosis (t0) assumed as 100% in predicting biochemical relapse and in differentiating them from PSA Bounces.
  • CONCLUSIONS: PP might represent an early and useful tool, predictive of clinical outcome in patients after BT for prostate cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28642046.001).
  • [ISSN] 1873-1449
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Biochemical failure / Interstitial brachytherapy / PSA bounces / PSA percentage / Prostate cancer
  •  go-up   go-down


9. Tiedje D, Quer O, Breil B, Schrader AJ, Bothe C, Kruse K, Bögemann M, Donner-Banzhoff N, Semjonow A: [Use of the S3 guidelines for early detection of prostate cancer in urological practices]. Urologe A; 2017 Jul;56(7):910-916
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of the S3 guidelines for early detection of prostate cancer in urological practices].
  • [Transliterated title] Anwendung der S3-Leitlinie zur Prostatakrebsfrüherkennung in urologischen Praxen.
  • OBJECTIVES: The German S3 guideline on prostate cancer gives recommendations on early detection of prostate cancer.
  • We developed 23 questions relating to 12 recommendations of the paragraphs of the S3 guidelines dealing with early detection of prostate cancer and prostate biopsy.
  • Reasons for deviations from "strong recommendations" are the following: information about advantages and disadvantages of early detection for prostate cancer, recommendation of a prostate biopsy in case of PSA level ≥4 ng/ml, and indication for repeat biopsy.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1994 May;151(5):1283-90 [7512659.001]
  • [Cites] Int J Qual Health Care. 2007 Dec;19(6):349-57 [17872937.001]
  • [Cites] BMJ Open. 2015 Dec 29;5(12 ):e008073 [26715477.001]
  • [Cites] Lancet Oncol. 2010 Aug;11(8):725-32 [20598634.001]
  • [Cites] Urologe A. 2014 Oct;53(10):1500-3 [24984950.001]
  • (PMID = 28280863.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Adherence / Focus groups / Interview / Prostate biopsy / Prostate cancer
  •  go-up   go-down


10. Walker DM, McAlearney AS, Sova LN, Lin JJ, Abramson S, Bickell NA: Comparing Prostate Cancer Treatment Decision Making in a Resource-rich and a Resource-poor Environment: A Tale of two Hospitals. J Natl Med Assoc; 2016 Winter;108(4):211-219

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparing Prostate Cancer Treatment Decision Making in a Resource-rich and a Resource-poor Environment: A Tale of two Hospitals.
  • OBJECTIVE: Black men with prostate cancer are diagnosed later, have poorer treatment outcomes, and higher mortality from the disease than all other racial groups.
  • While existing literature has explored differences in the treatment decision making process between black and white men with localized prostate cancer, little is known about how environmental factors may affect the treatment decision process for men with clinically significant disease for whom treatment improves survival.
  • Patients were identified through retrospective review of pathology and tumor registries; their charts abstracted to ascertain treatments.
  • CONCLUSION: These findings identify both medical-system factors, and practice-level factors that can help guide the development of interventions to reduce prostate cancer treatment disparities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 National Medical Association. Published by Elsevier Inc. All rights reserved.
  • (PMID = 27979006.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Decision-making / Disparities / Prostate cancer / Underserved populations
  •  go-up   go-down






Advertisement